A Phenethylamine That Targets an Enzyme, Not Nerves
Selegiline belongs to the phenethylamine chemical family, the same molecular backbone underlying substances as varied as amphetamines, mescaline, and MDMA. Yet its mechanism bears little resemblance to that of a classic stimulant: instead of directly driving the nervous system, it halts an enzyme responsible for recycling neurotransmitters.
That enzyme is monoamine oxidase, which exists in two forms. MAO-A metabolizes norepinephrine, serotonin, and dopamine; MAO-B primarily targets dopamine. Selegiline selectively blocks MAO-B, meaning dopamine degrades more slowly and remains available longer, particularly along the nigrostriatal pathways linked to motor control.
Why It Doesn’t Feel Like Cocaine
The effect attributed to it is not the typical sympathetic jolt of fast-acting stimulants, which spike rapidly and then crash with a characteristic comedown. Those who have described it speak instead of a “smooth, generalized activation”: a subtle sense of increased energy, mood, and drive, stemming from a shift in neuronal equilibrium rather than an acute neurotransmitter dump. This distinct profile is precisely what fueled the most ambitious promises surrounding the molecule—claims that, it is worth remembering, almost always outpace the available evidence.
Joseph Knoll and the Birth of Deprenyl
The substance was synthesized in Hungary during the 1960s. Behind it was Joseph Knoll, born in 1925 in Kassa (then Hungarian, now Košice in Slovakia). Of Jewish descent, he survived the Auschwitz, Ohrdruf, and Dachau concentration camps during World War II, while his parents were murdered in the gas chambers. He earned his medical degree from the University of Budapest in 1951 and eventually led the Department of Pharmacology at Semmelweis University’s Faculty of Medicine.
His fascination with the physiology of motivation—why certain individuals are driven by an internal impulse while others are not—led him to search for a molecule that combined something of the stimulating quality of amphetamines with the energizing action of monoamine oxidase inhibitors. Alongside chemist Zoltán Ecsery, who was already working with phenethylamines at the Hungarian pharmaceutical firm Chinoin (later absorbed into Sanofi), roughly thirty compounds were synthesized in 1961. Knoll selected the one lab-named “E-250,” later known as deprenyl. It was a racemic mixture of two isomers—identical formula, different spatial arrangement—from which he isolated the one that would be named selegiline.
The first paper appeared in Hungarian in 1964 and in English the following year. In 1971, Knoll demonstrated that the molecule selectively inhibits the B isoform of the enzyme.
The Tyramine Issue
This selectivity matters for a well-known safety reason. Non-selective monoamine oxidase inhibitors require strict dietary restrictions: foods rich in the amino acid tyramine—aged cheeses, yeast and meat extracts, cured meats, pickled goods, wine, and beer, among others—can trigger the dangerous “cheese reaction,” posing risks of hypertensive crisis, cerebral hemorrhage, or heart attack. Because selegiline spares MAO-A at low doses, it avoids this issue, which was historically celebrated as one of its major advantages. That selectivity, however, is not absolute and depends heavily on dosage: at high amounts, it loses its “clean” profile, and the dietary precautions of traditional MAOIs re-emerge.
Neuroprotection and “Smart Drug” Claims
Three main properties are often attributed to selegiline. First, enhancing dopamine availability and slowing its age-related decline. Second, a potential neuroprotective effect: by reducing oxidation generated during dopamine breakdown—and, with it, free-radical damage—some have proposed that it could slow down neurodegenerative processes. Third, a role as a cognitive enhancer or “smart drug,” prompting some healthy individuals to experiment with it on their own.
Knoll himself was an enthusiastic champion: he took it regularly and eventually recommended it to the general adult population. That leap—from a medication with specific clinical indications to an everyday longevity supplement—is precisely where responsible science reporting needs to hit the brakes.
A Critical Assessment
It is vital to separate established pharmacology from optimistic promises. That selegiline inhibits MAO-B and elevates dopamine levels is textbook biochemistry; that it is indicated for Parkinson’s disease and, in certain formulations, major depression is established clinical medicine. But the narrative of a “smooth booster for everyone” largely originates from its own discoverer, who was simultaneously an active researcher and a convinced personal user—a bias that calls for caution, not faith.
The notion of a neuroprotective effect that slows brain aging remains a subject of debate, and human trials have yielded results that are, at best, modest and disputed. Furthermore, “nootropic” use in healthy people lacks the solid evidence needed to treat a prescription drug as if it were a harmless dietary supplement.
From a harm reduction perspective, the critical takeaway is this: selegiline acts directly on the monoaminergic system and therefore carries serious interaction risks. Combining it with serotonergic agents—antidepressants, certain pain medications, substances like MDMA, or other phenethylamines—can trigger potentially life-threatening serotonin syndrome. At higher doses, the hypertensive and dietary warnings characteristic of non-selective MAOIs return. This is no minor detail; it is the line between a medically supervised therapy and reckless self-administration. For this reason, you will find no dosage regimens or purchasing tips here; its use belongs solely in the hands of a qualified healthcare provider familiar with the individual’s medical history and current prescriptions.
